The surprising effect of stress on your brain’s reward system
Science Daily: Pharmacology News
DECEMBER 4, 2024
Some people bounce back from trauma, but others get caught in depressive loops that sap the joy from their lives.
Sat.Nov 30, 2024 - Fri.Dec 06, 2024
266 
Scientific workflow for hypothesis testing in drug discovery: Part 1
Drug Target Review
DECEMBER 6, 2024
In drug discovery and biological research, the scientists workflow often follows a structured and iterative approach to ensure accuracy, reproducibility and scientific integrity. This article outlines the various stages of such a workflow, from hypothesis generation to data cleaning and interpretation, referencing the project workflow diagram (Figure 1).
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Role of Artificial Intelligence (AI) and Machine Learning (ML) in Drug Repurposing
Drug Patent Watch
DECEMBER 3, 2024
In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).
Agility with Complex Data Sets – Integration of Predicted and Empirical Data for Drug Discovery
Collaborative Drug
DECEMBER 6, 2024
We recently hosted an insightful webinar featuring the team from Congruence Therapeutics , who shared how they're using CDD Vault alongside their proprietary systems to manage complex drug discovery data. The impressive lineup of speakers included Maximilian Ebert (Executive Director of Computational Chemistry), Jeremy Dupaul-Chicoine (Associate Director of Biology), and Lee Fader (Vice President of Chemistry).
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Unlock the full potential of 3D cell culture with positive displacement dispensing
sptlabtech
DECEMBER 6, 2024
The growing importance of 3D cell culture 3D cell culture has become an essential tool for advancing research in biology, medicine, and drug discovery. Unlike traditional two-dimensional cell culture, in which cells are grown on a flat surface, 3D cell culture allows cells to interact in a more natural, biologically-relevant three-dimensional environment. 3D models better replicate the in vivo conditions that are critical for studying biological processes and disease progression, whilst providin
Design and Development of Novel Hybrids Based on Pyrrolo[2,1‐f][1,2,4]Triazine and 1‐(Methylpiperidin‐4‐yl) Aniline–Based Analogs: Exploring the Utility as Anticancer Agents via MERTK Inhibition
Chemical Biology and Drug Design
DECEMBER 5, 2024
A hybrid drug design approach was employed to develop novel leads ( 1K11K5 ). The molecules were synthesized via a multi-step synthetic approach and were assessed for their anticancer potential via cell viability studies, DMPK studies, and MERTK inhibition. Studies were corroborated by in silico studies. ABSTRACT Mer-tyrosine kinase (MERTK), a member of the AXL, TYRO3, and MERTK (TAM) family, is one of the promising targets for cancer treatment.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
More Trending
How GPCR agonists, including antibodies, are shaping the future of metabolic care
Drug Target Review
DECEMBER 4, 2024
G protein-coupled receptors (GPCRs) represent a cornerstone of modern drug discovery due to their crucial role in regulating human physiology and their involvement in numerous diseases. Many of these receptors are key targets for addressing obesity and metabolic disorders. Confo Therapeutics , led by CEO Dr Cedric Ververken, is at the forefront of developing innovative GPCR-targeted therapies using its proprietary ConfoBody ® platform.
Optimizing Generic Drug Development with Machine Learning
Drug Patent Watch
DECEMBER 4, 2024
The pharmaceutical industry is undergoing a significant transformation with the advent of machine learning methods. These methods have the potential to revolutionize the drug discovery process by enhancing the efficiency and accuracy of identifying and developing new drug candidates.
TRIM16 and PRC1 Are Involved in Pancreatic Cancer Progression and Targeted by Delphinidin
Chemical Biology and Drug Design
DECEMBER 5, 2024
Three pancreatic cancer-related microarray datasets (GSE183795, GSE28735, and GSE62452) were integrated. Analysis of differentially expressed genes, WGCNA, and machine learning algorithms (LASSO, XGboost, and random forest) were combined to identify genes associated with the progression of pancreatic cancer. Natural drugs, including delphinidin, which target the core genes, tripartite motif containing 16 (TRIM16), and protein regulator of cytokinesis 1 (PRC1), were then identified.
Integrating Real-World Data into Coveo Search Using the Generic REST API Source Connector
Perficient: Drug Development
DECEMBER 3, 2024
This blog will guide you through indexing content from API endpoints into Coveo using the Generic REST API source. This tool allows the indexing of data from any web service exposing a REST API, such as Content Management Systems (CMS), databases, or third-party platforms. While the demo API here is for illustration, the steps can be adapted for real-world scenarios, like integrating Adobe Experience Manager (AEM) data or fetching structured content, such as user profiles or metadata, from vario
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Atlas XIV And Reflections On The VC Math Problem
LifeSciVC
DECEMBER 5, 2024
Today we announced the closing of Atlas Venture Fund XIV , a $450M investment vehicle focused exclusively on early stage biotech investing. With the closing of Fund XIV, we’re privileged to be able to continue backing innovative new biotech companies for another fund cycle, reinforcing our science-first and seed-led venture creation model for novel therapeutics – and delivering on our mission of doing well by doing good.
Common Reasons for Drug Patent Rejections and Solutions
Drug Patent Watch
DECEMBER 3, 2024
The process of obtaining a patent for a drug invention can be complex and time-consuming. Despite the best efforts of inventors and patent attorneys, many drug patent applications are rejected by patent offices. Understanding the common reasons for these rejections is crucial for overcoming them and securing patent protection for innovative pharmaceuticals.
FDA Issues “Cliffs Notes”-style Guidance on Cell and Gene Therapy; What Questions Did They Answer? (Part 1)
FDA Law Blog: Drug Discovery
DECEMBER 6, 2024
By Mark A. Tobolowsky & Charles G. Raver & James E. Valentine On November 19, 2024, FDA released a draft guidance titled Frequently Asked Questions Developing Potential Cellular and Gene Therapy Products. As much of the content of this draft guidance for cellular and gene therapy (CGT) products is articulated elsewhere, this document serves as a one-stop shop or Cliffs Notes for the numerous guidance documents now covering CGT product development.
Secure Salesforce Integrations
Perficient: Drug Development
DECEMBER 4, 2024
In today’s interconnected world, Salesforce is rarely used in isolation. Integrating it with external systems—like ERPs, marketing platforms, or data warehouses—is crucial for seamless data exchange. But with integration comes the responsibility of securing your data pipeline. A poorly secured integration can expose sensitive business data, leading to compliance risks, financial losses, and reputational damage.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Four Revelations from Minnesota’s First 340B Transparency Report
Drug Channels
DECEMBER 3, 2024
It’s time to pay attention to the money behind the 340B curtain. Minnesota just released the industry‘s first ever mandated financial report on the 340B Drug Pricing Program. Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more. There are important limitations to these data.
New Business Models for Pharmaceutical Marketing: Transforming Data into Market Domination
Drug Patent Watch
DECEMBER 2, 2024
The traditional marketing models that once dominated the pharmaceutical industry are rapidly becoming obsolete, paving the way for innovative approaches that leverage technology, data, and patient-centricity. This comprehensive guide explores the new business models reshaping pharmaceutical marketing, offering insights into how companies can transform their strategies to achieve market domination.
How did humans and dogs become friends? Connections in the Americas began 12,000 years ago
Science Daily: Pharmacology News
DECEMBER 4, 2024
A new study sheds light on how long humans in the Americas have had relationships with the ancestors of today's dogs -- and asks an 'existential question': What is a dog?
Responsible AI: Expanding Responsibility Beyond the Usual Suspects
Perficient: Drug Development
DECEMBER 4, 2024
In the world of AI, we often hear about “Responsible AI.” However, if you ask ten people what it actually means, you might get ten different answers. Most will focus on ethical standards: fairness, transparency, and social good. But is that the end of responsibility? Many of our AI solutions are built by enterprise organizations who aim to meet both ethical standards AND business objectives.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
BioPharma Drive: Drug Pricing
DECEMBER 4, 2024
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
Zepbound Bests Wegovy for Weight Loss in New Trial
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly."Given the increased interest around obesity medications, we conducted.
20th century lead exposure damaged American mental health
Science Daily: Pharmacology News
DECEMBER 4, 2024
Exposure to car exhaust from leaded gas during childhood altered the balance of mental health in the U.S. population, making generations of Americans more depressed, anxious and inattentive or hyperactive, according to researchers. They estimate that 151 million cases of psychiatric disorder over the past 75 years have resulted from American children's exposure to lead.
Effortless Development of LWCs in Local Dev
Perficient: Drug Development
DECEMBER 2, 2024
The Salesforce Winter ’25 Release unveils an exciting feature for developers: Local Dev (Beta). This cutting-edge tool allows developers to create Lightning Web Components (LWCs) with a real-time preview of their Lightning app or Experience Cloud site using the Lightning Web Runtime. With Local Dev, code changes are instantly reflected in the browser, streamlining the development process and boosting productivity.
Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Diabetes advocacy group discourages use of compounded GLP-1 drugs
BioPharma Drive: Drug Pricing
DECEMBER 2, 2024
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.
Could High-Fructose Corn Syrup in Foods Help Speed Cancer?
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- The sugar known as fructose could be a kind of rocket fuel for cancer cells, and lowering fructose intake could be one way to fight the disease, new research suggests.Fructose is already ubiquitous in American diets, due.
Hidden fat predicts Alzheimer's 20 years ahead of symptoms
Science Daily: Pharmacology News
DECEMBER 2, 2024
Researchers have linked a specific type of body fat to the abnormal proteins in the brain that are hallmarks of Alzheimer's disease up to 20 years before the earliest symptoms of dementia appear, according to a new study. The researchers emphasized that lifestyle modifications targeted at reducing this fat could influence the development of Alzheimer's disease.
EF Core: Stored Procedure Multiple Result Sets
Perficient: Drug Development
DECEMBER 2, 2024
Stored procedures are powerful tools for running complex database operations efficiently. EF Core execute stored procedure multiple result sets, a technique that can improve performance and simplify data retrieval. It’s important to handle the results properly when working with stored procedures that return multiple tables. Entity Framework Core allows you to execute stored procedures and process multiple result sets.
Janux impresses Wall Street with new prostate cancer drug results
BioPharma Drive: Drug Pricing
DECEMBER 3, 2024
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
Dec 2024 - Q4 Product Update Webinar: Curves and AI
Collaborative Drug
DECEMBER 4, 2024
We recently hosted our December 2024 Q4 Product Update Webinar, showcasing significant enhancements to the CDD Vault platform. The webinar covered four key modules: Curves and AI. Let's dive into the exciting updates for each module.
Tiny, daily bursts of vigorous incidental physical activity could almost halve cardiovascular risk in middle-aged women
Science Daily: Pharmacology News
DECEMBER 3, 2024
An average of four minutes of incidental vigorous physical activity a day could almost halve the risk of major cardiovascular events, such as heart attacks, for middle-aged women who do not engage in structured exercise, according to new research.
Salesforce Einstein One: Your AI-Powered Salesforce Assistant
Perficient: Drug Development
DECEMBER 4, 2024
Understanding Salesforce’s Einstein One: The Unified AI Powerhouse Salesforce has long been at the forefront of digital transformation, providing comprehensive tools to help businesses stay ahead in a fast-paced environment. One of its most significant advancements is Einstein One, a unified AI platform designed to elevate Salesforce users’ capabilities by integrating advanced artificial intelligence across its suite of products.
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
BioPharma Drive: Drug Pricing
DECEMBER 4, 2024
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide drug data.
New Weight-Loss Advance: A Gastric Balloon You Control to Feel Full or Not
Drugs.com
DECEMBER 3, 2024
TUESDAY, Dec. 3, 2024 -- GLP-1 meds are all the rage for weight loss nowadays, but not everyone can safely take the drugs to shed pounds. Invasive weight-loss surgeries can often be a tough sell, too. Now, researchers at the Massachusetts Institute.
Let's personalize your content